Profiling the acute phase antibody response against mpox virus in patients infected during the 2022 outbreak

被引:11
作者
Colavita, Francesca [1 ]
Matusali, Giulia [1 ]
Mazzotta, Valentina [2 ]
Bettini, Aurora [1 ]
Lapa, Daniele [1 ]
Meschi, Silvia [1 ]
Francalancia, Massimo [1 ]
Pinnetti, Carmela
Bordi, Licia [1 ]
Mizzoni, Klizia [1 ]
Coen, Sabrina [1 ]
Girardi, Enrico [3 ]
Vaia, Francesco [4 ]
Nicastri, Emanuele
Antinori, Andrea [2 ]
Maggi, Fabrizio [1 ]
机构
[1] Natl Inst Infect Dis, Lab Virol, Lazzaro Spallanzani IRCCS, Rome, Italy
[2] Natl Inst Infect Dis, Clin & Res Infect Dis Dept, Lazzaro Spallanzani IRCCS, Rome, Italy
[3] Natl Inst Infect Dis, Sci Direct, Lazzaro Spallanzani IRCCS, Rome, Italy
[4] Natl Inst Infect Dis, Gen Direct, Lazzaro Spallanzani IRCCS, Rome, Italy
基金
欧盟地平线“2020”;
关键词
humoral response; mpox virus; neutralizing antibody; MONKEYPOX; IMMUNITY;
D O I
10.1002/jmv.28851
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Information on the immune response during the mpox virus (MPXV) infection is still scarce or limited to past studies when cross-reactive immunity from smallpox vaccination was predominant. Here, we describe the short-term kinetics of the antibody response in patients with acute MPXV infection during the 2022 multicountry outbreak. A total of 64 samples from 18 MPXV-positive patients were longitudinally collected from the day of symptom onset (DSO) up to 20 days after and tested for anti-MPXV immunoglobulin G (IgG), IgM, IgA, and neutralizing antibodies (nAb) using the whole-live virus isolated in May 2022. IgG, IgM, and IgA were detected as early as 4 DSO (median time of seroconversion 7.5 DSO for IgG, 8 DSO for IgM and IgA). Anti-MPXV nAb were detectable in samples collected as early as 1 week after symptoms, with stable levels up to 20 DSO. After 2 weeks, IgG and nAb reached high titers. No significant differences were observed regardless of status of smallpox vaccination, human immunodeficiency virus positivity, or disease severity. Significant lower levels of IgM and IgG were observed in the patients treated with antivirals. These results contribute to extending the knowledge of the MPXV infection and the antibody response in a population with no historic smallpox vaccination.
引用
收藏
页数:8
相关论文
共 26 条
[1]   People with asymptomatic or unrecognised infection potentially contribute to monkeypox virus transmission [J].
Accordini, Silvia ;
Cordioli, Maddalena ;
Pomari, Elena ;
Tacconelli, Evelina ;
Castilletti, Concetta .
LANCET MICROBE, 2023, 4 (04) :E209-E209
[2]   Clinical features and management of human monkeypox: a retrospective observational study in the UK [J].
Adler, Hugh ;
Gould, Susan ;
Hine, Paul ;
Snell, Luke B. ;
Wong, Waison ;
Houlihan, Catherine F. ;
Osborne, Jane C. ;
Rampling, Tommy ;
Beadsworth, Mike Bj ;
Duncan, Christopher Ja ;
Dunning, Jake ;
Fletcher, Tom E. ;
Hunter, Ewan R. ;
Jacobs, Michael ;
Khoo, Saye H. ;
Newsholme, William ;
Porter, David ;
Porter, Robert J. ;
Ratcliffe, Libuse ;
Schmid, Matthias L. ;
Semple, Malcolm G. ;
Tunbridge, Anne J. ;
Wingfield, Tom ;
Price, Nicholas M. .
LANCET INFECTIOUS DISEASES, 2022, 22 (08) :1153-1162
[3]   Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study [J].
Agrati, Chiara ;
Cossarizza, Andrea ;
Mazzotta, Valentina ;
Grassi, Germana ;
Casetti, Rita ;
De Biasi, Sara ;
Pinnetti, Carmela ;
Gili, Simona ;
Mondi, Annalisa ;
Cristofanelli, Flavia ;
Lo Tartaro, Domenico ;
Notari, Stefania ;
Maffongelli, Gaetano ;
Gagliardini, Roberta ;
Gibellini, Lara ;
Aguglia, Camilla ;
Lanini, Simone ;
D'Abramo, Alessandra ;
Matusali, Giulia ;
Fontana, Carla ;
Nicastri, Emanuele ;
Maggi, Fabrizio ;
Girardi, Enrico ;
Vaia, Francesco ;
Antinori, Andrea .
LANCET INFECTIOUS DISEASES, 2023, 23 (03) :320-330
[4]  
ASHLEY RL, 1984, J CLIN INVEST, V73, P681, DOI 10.1172/JCI111260
[5]  
Cohn H, 2023, medRxiv, DOI [10.1101/2023.03.07.23286701, 10.1101/2023.03.07.23286701, DOI 10.1101/2023.03.07.23286701]
[6]   Kinetics of viral DNA in body fluids and antibody response in patients with acute Monkeypox virus infection [J].
Colavita, Francesca ;
Mazzotta, Valentina ;
Rozera, Gabriella ;
Abbate, Isabella ;
Carletti, Fabrizio ;
Pinnetti, Carmela ;
Matusali, Giulia ;
Meschi, Silvia ;
Mondi, Annalisa ;
Lapa, Daniele ;
Vita, Serena ;
Minosse, Claudia ;
Aguglia, Camilla ;
Gagliardini, Roberta ;
Specchiarello, Eliana ;
Bettini, Aurora ;
Nicastri, Emanuele ;
Girardi, Enrico ;
Vaia, Francesco ;
Antinori, Andrea ;
Maggi, Fabrizio .
ISCIENCE, 2023, 26 (03)
[7]  
ECDC, 2022, FACTSH HLTH PROF MPO
[8]   Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections [J].
Gilchuk, Iuliia ;
Gilchuk, Pavlo ;
Sapparapu, Gopal ;
Lampley, Rebecca ;
Singh, Vidisha ;
Kose, Nurgun ;
Blum, David L. ;
Hughes, Laura J. ;
Satheshkumar, Panayampalli S. ;
Townsend, Michael B. ;
Kondas, Ashley V. ;
Reed, Zachary ;
Weiner, Zachary ;
Olson, Victoria A. ;
Hammarlund, Erika ;
Raue, Hans-Peter ;
Slifka, Mark K. ;
Slaughter, James C. ;
Graham, Barney S. ;
Edwards, Kathryn M. ;
Eisenberg, Roselyn J. ;
Cohen, Gary H. ;
Joyce, Sebastian ;
Crowe, James E., Jr. .
CELL, 2016, 167 (03) :684-+
[9]   Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus [J].
Hsueh, PR ;
Huang, LM ;
Chen, PJ ;
Kao, CL ;
Yang, PC .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (12) :1062-1066
[10]   Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection [J].
Karem, Kevin L. ;
Reynolds, Mary ;
Hughes, Christine ;
Braden, Zach ;
Nigam, Pragati ;
Crotty, Shane ;
Glidewell, John ;
Ahmed, Rafi ;
Amara, Rama ;
Damon, Inger K. .
CLINICAL AND VACCINE IMMUNOLOGY, 2007, 14 (10) :1318-1327